-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Pro
Author: Haimer
Parkinson's disease (PD) is the most common neurodegenerative disease except Alzheimer's disease (AD), affecting millions of people worldwide
A new research paper published in the top journal Nature on November 3 answered this question and provided new ideas for the treatment of PD
We know that mitochondria are the "energy factories" of cells, providing a steady stream of energy for the body through respiration
The function of mitochondria is inseparable from the activities of a variety of enzyme complexes, one of which is called complex I is closely related to the progress of PD
Neurodegeneration stage in PD mouse model (Source: Nature)
The researchers found that the mitochondrial dysfunction of mice that knocked out NDUFS2 showed a series of neurodegenerative symptoms in the next few months
Mice have axon damage after knocking out NDUFS2 (Source: Nature)
This study shows that the damage of mitochondria in dopaminergic neurons is sufficient to cause PD
Note: The original text has been deleted
Reference materials:
[1] Patricia González-Rodríguez et al.
[2] Gene therapy boosts Parkinson's disease drug benefits.
[3] Zak Doric & Ken Nakamura.
